Full Circles Therapeutics, a leader in next-generation genome engineering, announces that the United States Patent and Trademark Office (USPTO) has allowed its foundational patent titled”TARGETED GENOME MODIFICATION USING CIRCULAR SINGLE-STRANDED DNA.”This patent protects Full Circles' innovative platform, which enablesprecise, efficient, and non-viral genome modificationusing circular single-stranded DNA (cssDNA), overcoming key challenges in genome engineering.
This breakthrough provides asafer, modular, and scalable alternative to viral vectors and traditional double-stranded DNA (dsDNA) donors, improving gene integration efficiency while minimizing immunogenicity, cytotoxicity, and off-target effects. With broad applications incell and gene therapy, regenerative medicine, and biomedical research, this platform is poised to transform the field of genetic modification.
Advancing Genome Engineering with cssDNA
The growing demand forsafe and efficient genome editing technologieshas highlighted the limitations of viral-based gene transfer methods, such as lentiviral and adeno-associated virus (AAV) vectors, which present risks of unpredictable genomic integration, immunogenicity, and manufacturing challenges.
Full Circles'cssDNA-based technology, dubbed C4DNA™GATALYST™genome engineering platform, enables targeted transgene integration via homology-directed repair (HDR) without the risks of viral vectors, improving precision while reducing toxicity. This makes it ideal fornext-generation, virus-free therapeutic applications.
“The allowance of this patent is a significant milestone in advancing non-viral genome editing,” saidRichard Shan, co-founder and Chairman of Full Circles Therapeutics. “Our proprietary cssDNA platform offers a safer and more precise alternative for gene modification, paving the way for improved allogeneic cell therapies, CAR-NK and CAR-T therapies, and other transformative treatments.”
Open for Licensing and Collaboration
To accelerate innovation,Full Circles Therapeutics is actively seeking licensing and partnership opportunitiesfor its cssDNA platform across thebiotechnology and pharmaceutical industries.
“We believe C4DNA™GATALYST™technology has immense potential across oncology, autoimmune diseases, regenerative medicine, and beyond,” saidHoward Wu, co-founder and CSO. “By offering this platform for licensing, we aim to empower other innovators to enhance their gene editing capabilities and advance safer, faster, more affordable and effective therapies.”
Contact for Licensing Inquiries
For Media & Licensing Inquiries:Flora ZhangDirector of Communications, Full Circles TherapeuticsPhone: (410) 733-0130Email: 391251@email4pr.com
About Full Circles Therapeutics
Full Circles Therapeutics is a pioneering biotechnology company advancing genome engineering through innovative, non-viral gene editing technologies. Its proprietary cssDNA platform is designed toenable safer, more efficient, and scalable genetic modifications, revolutionizing next-generation cell and gene therapies.
For more information, visitwww.fullcirclestx.com.
https://c212.net/c/img/favicon.png?sn=PH35768&sd=2025-03-07
View original content:https://www.prnewswire.com/news-releases/full-circles-therapeutics-secures-us-patent-allowance-for-targeted-genome-modification-using-circular-single-stranded-dna-302395179.html
SOURCE Full Circles Therapeutics
https://rt.newswire.ca/rt.gif?NewsItemId=PH35768&Transmission_Id=202503070858PR_NEWS_USPR_____PH35768&DateId=20250307